Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Accountprinceon Mar 04, 2024 8:48pm
272 Views
Post# 35914778

Vantive In Play

Vantive In PlayNow that Baxter has disclosed that Vantive is in play does that put Spectral in play?  We don't have all the details of the Baxter/Vantive deal with Spectral so we can only go with the 20 year exclusive rights to EAA and PMX with each party getting around a third of the revenue.  No other details given so we can assume that Baxter/Vantive do not have any other material rights or preemptive rights with Spectral.

So if private equity is now sniffing around would they be aware of our little gem?  If they read the Vantive material they would see EAA and PMX featured so likely would ask the question and be given answers.  Would they recognize the extent of achievements and where we are with Tigris?  Would they also conclude that success is highly probable?  Would they view doing a takeover of Spectral as a win-win with very low risk?  If they buy Spectral now and also succeed in buying Vantive they would have strong cashflow from both on the same product.  If they don't buy Vantive but do buy Spectral they would have that strong cashflow with Vantive doing all the heavy lifting for them.

This is a very interesting development.  Is this unknown wallflower about to come of age?  Private equity can smell money and they go after what they want.  Time to fasten our seatbelts as this could become quite interesting.  Thoughts and comments from all the real shareholders are invited. 
<< Previous
Bullboard Posts
Next >>